Klastersky J, Sculier J P
Semin Oncol. 1985 Dec;12(4 Suppl 6):38-48.
Cisplatin (Platinol)-containing regimens, especially in combination with etoposide (VP-16) (VePesid), vindesine, and/or mitomycin-C, have proven beneficial to patients with non-small-cell lung cancer. A reproducible response rate of 30% to 40% has been achieved. Because current therapies are greatly in need of improvement, patients with non-small-cell lung cancer--especially those who have a good performance status and thus are more likely to respond--should be considered for participation in clinical studies in which the control regimens are associated with moderate response rates. Although chemotherapy affords some benefit to nonresponding patients, they might participate in phase I or phase II trials rather than continue treatment more likely to be toxic than beneficial.
含顺铂（铂尔定）的治疗方案，特别是与依托泊苷（威克）、长春地辛和/或丝裂霉素-C联合使用时，已被证明对非小细胞肺癌患者有益。已实现30%至40%的可重复缓解率。由于目前的治疗方法急需改进，非小细胞肺癌患者——尤其是那些身体状况良好、因此更有可能产生反应的患者——应考虑参与对照方案具有中等缓解率的临床研究。尽管化疗对无反应的患者有一定益处，但他们可能参加I期或II期试验，而不是继续接受毒性可能大于益处的治疗。
